Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer (Q50265287)

28 February 2018

title

Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer (English)

1 reference

28 February 2018

0 references

Qing-Ming Xiang

1

1 reference

28 February 2018

Lin-Wei Wang

2

1 reference

28 February 2018

Jing-Ping Yuan

3

1 reference

28 February 2018

Jia-Mei Chen

4

1 reference

28 February 2018

Fang Yang

5

1 reference

28 February 2018

Yan Li

6

1 reference

28 February 2018

publication date

20 June 2015

1 reference

28 February 2018

Experimental and Molecular Pathology

published in

1 reference

28 February 2018

volume

99

1 reference

28 February 2018

issue

1

1 reference

28 February 2018

page(s)

133-138

1 reference

28 February 2018

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

The HER2 testing conundrum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Tapping The Potential of Quantum Dots for Personalized Oncology: Current Status and Future Perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Cancer incidence and mortality in china, 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Tumor invasion unit in gastric cancer revealed by QDs-based in situ molecular imaging and multispectral analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Trastuzumab--mechanism of action and use in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Correlation between Ki67 and breast cancer prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Global cancer statistics, 2012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Computer-based image studies on tumor nests mathematical features of breast cancer and their clinical prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Quantum dots-based tissue and in vivo imaging in breast cancer researches: current status and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Ki67 in breast cancer: prognostic and predictive potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Comparative validation of the SP6 antibody to Ki67 in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

Cancer survival in China, 2003-2005: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2015.06.013

10.1016/J.YEXMP.2015.06.013

7 January 2021

Identifiers

DOI

1 reference

28 February 2018

1 reference

28 February 2018